Celltrion Pharm Shares Outstanding vs. Total Debt

068760 Stock  KRW 59,800  1,300  2.13%   
Taking into consideration Celltrion Pharm's profitability measurements, Celltrion Pharm may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in January. Profitability indicators assess Celltrion Pharm's ability to earn profits and add value for shareholders.
For Celltrion Pharm profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Celltrion Pharm to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Celltrion Pharm utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Celltrion Pharm's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Celltrion Pharm over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
Please note, there is a significant difference between Celltrion Pharm's value and its price as these two are different measures arrived at by different means. Investors typically determine if Celltrion Pharm is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Celltrion Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Celltrion Pharm Total Debt vs. Shares Outstanding Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Celltrion Pharm's current stock value. Our valuation model uses many indicators to compare Celltrion Pharm value to that of its competitors to determine the firm's financial worth.
Celltrion Pharm is number one stock in shares outstanding category among its peers. It is rated third in total debt category among its peers making up about  1,157  of Total Debt per Shares Outstanding. Comparative valuation analysis is a catch-all model that can be used if you cannot value Celltrion Pharm by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Celltrion Pharm's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

Celltrion Total Debt vs. Shares Outstanding

Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.

Celltrion Pharm

Shares Outstanding

 = 

Public Shares

-

Repurchased

 = 
34.05 M
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.

Celltrion Pharm

Total Debt

 = 

Bonds

+

Notes

 = 
39.4 B
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.

Celltrion Total Debt vs Competition

Celltrion Pharm is rated third in total debt category among its peers. Total debt of Health Care industry is presently estimated at about 226.75 Billion. Celltrion Pharm retains roughly 39.4 Billion in total debt claiming about 17% of equities under Health Care industry.
Total debt  Valuation  Workforce  Revenue  Capitalization

Celltrion Pharm Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Celltrion Pharm, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Celltrion Pharm will eventually generate negative long term returns. The profitability progress is the general direction of Celltrion Pharm's change in net profit over the period of time. It can combine multiple indicators of Celltrion Pharm, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Celltrion Pharm, Inc., a pharmaceutical company, develops and sells biosimilars and over-the-counter drugs in South Korea. Celltrion Pharm Inc. was founded in 1976 and is based in Cheongju, South Korea. Celltrionph is traded on Korean Securities Dealers Automated Quotations in South Korea.

Celltrion Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Celltrion Pharm. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Celltrion Pharm position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Celltrion Pharm's important profitability drivers and their relationship over time.

Use Celltrion Pharm in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Celltrion Pharm position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Celltrion Pharm will appreciate offsetting losses from the drop in the long position's value.

Celltrion Pharm Pair Trading

Celltrion Pharm Pair Trading Analysis

The ability to find closely correlated positions to Celltrion Pharm could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Celltrion Pharm when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Celltrion Pharm - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Celltrion Pharm to buy it.
The correlation of Celltrion Pharm is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Celltrion Pharm moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Celltrion Pharm moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Celltrion Pharm can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Celltrion Pharm position

In addition to having Celltrion Pharm in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Precious Metals ETFs Thematic Idea Now

Precious Metals ETFs
Precious Metals ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Precious Metals ETFs theme has 29 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Precious Metals ETFs Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Celltrion Stock

To fully project Celltrion Pharm's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Celltrion Pharm at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Celltrion Pharm's income statement, its balance sheet, and the statement of cash flows.
Potential Celltrion Pharm investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Celltrion Pharm investors may work on each financial statement separately, they are all related. The changes in Celltrion Pharm's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Celltrion Pharm's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.